Key insights
- Abbott Laboratories (ABT) stock hit a 52-week low, down 28.66% over the past year, despite meeting EPS expectations and showing slight sales growth in Q1. Challenges in diabetes and respiratory segments led to revenue misses on an organic basis. Several analysts lowered price targets, citing segment weakness and reduced organic guidance. While the stock appears technically oversold and offers a dividend, the company-specific headwinds suggest a near-term bearish outlook for ABT, potentially impacting broader healthcare sentiment.
Abbott Laboratories stock reached a 52-week low, trading at $93.91, reflecting a significant downturn over the past year. The healthcare giant’s market capitalization stands at $163.6 billion, with the stock trading at a P/E ratio of 26.42. According to InvestingPro analysis, the stock appears undervalued at current levels, suggesting potential upside for long-term investors. This price level marks a notable decline, as the company’s stock has experienced a 28.66% decrease in value over the last 12 months. The drop to this new low underscores the challenges faced by Abbott Laboratories in the current market environment, as investors continue to navigate economic uncertainties and industry-specific pressures. InvestingPro Tips indicate the stock’s RSI suggests oversold territory, while the company maintains an impressive 56-year streak of dividend payments with a current yield of 2.62%. For deeper insights, investors can access Abbott’s comprehensive Pro Research Report, one of 1,400+ available on the platform.
In other recent news, Abbott Laboratories reported its first-quarter results, which showed a 1% increase in worldwide sales, aligning with consensus expectations. However, the company faced challenges in its diabetes and respiratory segments, impacting revenue performance. Adjusted earnings per share met expectations, though revenue fell short of projections on an organic growth basis. Analysts have responded with several adjustments to Abbott’s stock price targets. Leerink Partners reduced their target to $106, citing mixed results across various divisions. Piper Sandler also lowered their target to $115, highlighting underperformance in the medical device segment, particularly in diabetes sales. TD Cowen adjusted their target to $115, referencing lowered organic guidance and weaknesses in specific product lines. Bernstein SocGen and RBC Capital also made downward adjustments, setting targets at $110 and $130, respectively, while maintaining positive ratings. These developments reflect a cautious outlook from analysts, focusing on the company’s mixed performance and specific segment challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates ABT alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if ABT is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?